Eloxx Pharmaceuticals ( (ELOX) ) has released a notification of late filing.
Eloxx Pharmaceuticals, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The primary reason for this delay is the company’s inability to allocate the necessary financial resources to engage an independent public accounting firm to audit its financial statements. This financial constraint is ongoing, and the company has not provided a specific timeline for when the filing will be completed. Eloxx Pharmaceuticals anticipates a significant increase in net loss and accumulated deficit for the year ended December 31, 2024, compared to the previous year, and has expressed substantial doubt about its ability to continue as a going concern. The notification was signed by Sumit Aggarwal, President and CEO, highlighting the company’s ongoing compliance efforts.
More about Eloxx Pharmaceuticals
Average Trading Volume: 225
Technical Sentiment Signal: Strong Buy
Current Market Cap: $3
For an in-depth examination of ELOX stock, go to TipRanks’ Stock Analysis page.